India Minimally Invasive Biopsy Techniques Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

The India Minimally Invasive Biopsy Techniques Market was valued at USD 89.31 Million in 2024, and is expected to reach USD 165.35 Million by 2030, rising at a CAGR of 10.77%. The India Minimally Invasive Biopsy Techniques Market is experiencing robust growth, driven by the rising prevalence of cancer, increasing demand for early disease detection, and advancements in biopsy technologies. The expanding healthcare infrastructure, particularly in urban regions like Delhi, Mumbai, Bengaluru, and Chennai, has facilitated the adoption of innovative biopsy techniques, reduced patient discomfort and improving diagnostic accuracy. Government initiatives promoting cancer screening programs and increased healthcare spending are fueling market expansion.

However, challenges such as the high cost of advanced biopsy instruments, limited accessibility in rural areas, and a shortage of skilled professionals continue to hinder widespread adoption. The market also faces regulatory hurdles, with stringent approval processes for new biopsy devices potentially delaying product launches. Despite these challenges, the rising awareness about minimally invasive procedures and the growing preference for liquid biopsies over traditional methods are expected to drive market growth, making India a key market for biopsy device manufacturers in the coming years.

Key Market Drivers

Rising Cancer Prevalence

The rising prevalence of cancer in India is a significant driver propelling the Minimally Invasive Biopsy Techniques Market, as early and accurate diagnosis remains critical in improving treatment outcomes. One in nine Indians is likely to develop cancer in their lifetime, making the disease a growing public health concern. Among the various cancer types, lung cancer is the leading malignancy among males, whereas breast cancer dominates among females, reflecting the urgent need for enhanced diagnostic capabilities. The overall incidence of cancer cases in India is expected to rise by 12.8% by 2025 compared to 2020, underscoring the increasing burden on healthcare infrastructure.

The surge in cancer cases can be attributed to multiple factors, including lifestyle changes, rising pollution levels, increasing tobacco consumption, and genetic predisposition. Urbanization and industrialization have led to greater exposure to environmental carcinogens, while shifting dietary habits and sedentary lifestyles have contributed to a higher risk of obesity-related cancers. India’s aging population is more vulnerable to malignancies, further escalating demand for precise and less invasive diagnostic procedures. In 2023, approximately a third of the total population in India lived in cities. The trend shows an increase of urbanization by more than 4 percent in the last decade, meaning people have moved away from rural areas to find work and make a living in the cities.

Key Market Challenges

High Cost of Advanced Biopsy Techniques

One of the significant challenges in the India Minimally Invasive Biopsy Techniques Market is the high cost associated with advanced biopsy procedures and equipment, which limits accessibility, particularly in lower-income and rural areas. While minimally invasive biopsy techniques such as liquid biopsy, fine-needle aspiration biopsy (FNAB), and image-guided biopsies offer numerous advantages, including reduced patient discomfort, quicker recovery times, and higher diagnostic accuracy, their high price points remain a barrier to widespread adoption.

The cost of liquid biopsy tests - which are gaining traction due to their ability to detect cancer using a simple blood sample - can range from INR 10,000 to INR 50,000 per test, making them unaffordable for a large segment of the population. Similarly, core needle biopsies and stereotactic biopsies require sophisticated imaging technologies such as MRI, CT scans, and ultrasound guidance, significantly increasing operational costs for healthcare providers. Many hospitals and diagnostic centers, especially in tier-2 and tier-3 cities, struggle to invest in these high-end diagnostic solutions due to financial constraints.

Moreover, the import dependency on biopsy instruments and reagents further escalates costs. India relies heavily on global manufacturers for advanced biopsy equipment, and fluctuations in foreign exchange rates, import duties, and supply chain disruptions contribute to price volatility. Unlike traditional biopsy methods, robotic-assisted biopsy systems and AI-driven pathology solutions, which offer higher precision, require substantial capital investment, restricting their availability to only a few premium healthcare institutions.

Key Market Trends

Growing Preference for Minimally Invasive Procedures

A significant trend shaping the India Minimally Invasive Biopsy Techniques Market is the growing preference for minimally invasive procedures, driven by increasing patient awareness, advancements in technology, and the rising burden of cancer. Traditional biopsy methods, such as surgical excision biopsies, are often associated with pain, longer recovery times, and higher risks of complications. In contrast, minimally invasive biopsy techniques, including liquid biopsy, fine-needle aspiration biopsy (FNAB), and image-guided core needle biopsy, offer greater precision, reduced patient discomfort, and faster recovery, making them the preferred choice among both patients and healthcare providers.

One of the key factors fueling this trend is technological advancements that have enhanced the accuracy and efficiency of minimally invasive biopsy techniques. Liquid biopsy, for instance, is gaining widespread acceptance as it enables non-invasive cancer detection through a simple blood draw, eliminating the need for surgical intervention. With increasing R&D investments, next-generation sequencing (NGS), circulating tumor DNA (ctDNA) analysis, and AI-driven pathology solutions are further improving biopsy accuracy, making early-stage cancer detection more effective.

Moreover, the demand for ambulatory and outpatient diagnostic solutions is rising, particularly in urban centers such as Delhi, Mumbai, Bengaluru, and Chennai, where patients seek quick, safe, and convenient diagnostic options. Hospitals and diagnostic centers are increasingly integrating robotic-assisted biopsy systems and AI-based imaging technologies to improve diagnostic precision and enhance patient outcomes. The private healthcare sector, which dominates India's diagnostic landscape, is actively investing in state-of-the-art minimally invasive biopsy solutions to meet the growing demand for advanced cancer diagnostics.

Key Market Players

• Hoffmann-La Roche AG
• Thermo Fisher Scientific, Inc.
• PerkinElmer Inc.
• QIAGEN India Pvt. Ltd.
• Cardinal Health International India Pvt Ltd
• B. Braun SE

Report Scope

In this report, the India Minimally Invasive Biopsy Techniques Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

India Minimally Invasive Biopsy Techniques Market, By Product:

• Tests
• Kits & Consumables
• Instruments

India Minimally Invasive Biopsy Techniques Market, By Technique:

• Liquid Biopsy
• Optical Biopsy
• Brush Biopsy
• Pigmented Lesion Assays
• Others

India Minimally Invasive Biopsy Techniques Market, By Circulating Biomarker:

• Circulating Tumor Cells (CTCs)
• Cell Free DNA (cfDNA)
• Circulating Tumor DNA (ctDNA)
• Extracellular Vesicles
• Others

India Minimally Invasive Biopsy Techniques Market, By Application:

• Clinical
• Therapeutic

India Minimally Invasive Biopsy Techniques Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Center
• Academic & Research Institutions

India Minimally Invasive Biopsy Techniques Market, By Region:

• East India
• West India
• North India
• South India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Minimally Invasive Biopsy Techniques Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.